DataLookout › Non-Hodgkin Lymphoma › MCL Clinical Trials

Mantle Cell Lymphoma Clinical Trial Landscape

MCL treatment is entering its third generation, from covalent BTK inhibitors to non-covalent inhibitors to BTK degraders, with CAR-T and bispecific antibodies reshaping the relapsed setting. Get a daily digest of the trials defining MCL care in 2026.

Track MCL Trials Free

Active Phase 3 MCL Programs (2026)

NCT IDDrug / MechanismSponsorPhaseStatus
NCT06742996 Sonrotoclax (BGB-11417) + zanubrutinib vs. placebo + zanubrutinib: BCL-2 inhibitor + BTKi in R/R MCL (CELESTIAL-RRMCL) BeOne Medicines Phase 3 Recruiting
19 trials we monitor in Mantle Cell Lymphoma are showing warning signs

A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.

TrialWarning signsStatus
Real-world Study of Acalabrutinib NCT06767891Primary completion moved at least 3 years 2 months later
Enrollment reduced 20%		Enrolling by Invitation

18 more on the Trials at Risk page. See which trials →

22 trials we monitor in Mantle Cell Lymphoma are due to complete in the next 6 months

Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.

TrialScheduledPhase
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or… NCT06054776Oct 16, 2026 · EstimatedPhase 2

21 more on the Completions page. See the calendar →

Active Phase 2 Programs

NCT IDDrug / MechanismSponsorStatus
NCT05529069 Pirtobrutinib + venetoclax: non-covalent BTKi + BCL-2i in R/R MCL MD Anderson Cancer Center Recruiting
NCT06263491 Pirtobrutinib + rituximab: non-covalent BTKi in previously untreated low/intermediate-risk MCL MD Anderson Cancer Center Recruiting
NCT07003295 Glofitamab: CD20xCD3 bispecific T-cell engager in MCL after CAR-T failure NCI Recruiting

Active Phase 1 / Early Programs

NCT IDDrug / MechanismSponsorStatus
NCT05006716 BGB-16673: BTK CDAC protein degrader in R/R B-cell malignancies including MCL BeOne Medicines Recruiting
NCT04830137 NX-2127: BTK/IKZF1/IKZF3 degrader in R/R B-cell malignancies including MCL Nurix Therapeutics Recruiting
NCT06026319 CD79b-19 CAR T cells: dual-antigen CAR-T in Non-Hodgkin Lymphoma including MCL Mass General / MGH Cancer Center Recruiting

Track MCL Trials

When CELESTIAL-RRMCL opens new sites or pirtobrutinib combination data is updated, you'll know the same day.

Start Free: No Credit Card

The MCL Treatment Landscape in 2026: The BTK Evolution

Mantle cell lymphoma is a mature B-cell lymphoma defined by the t(11;14) translocation, overexpression of cyclin D1 due to juxtaposition with the IGH locus. Despite being relatively uncommon (approximately 6% of all NHL cases), MCL has been a proving ground for some of oncology's most consequential drug classes.

The BTK inhibitor story in MCL illustrates the generation-by-generation evolution of targeted therapy: ibrutinib (first-generation, covalent) → acalabrutinib/zanubrutinib (second-generation covalent, improved selectivity) → pirtobrutinib (non-covalent, works in C481S-mutated BTKi-resistant disease) → BTK degraders (eliminate the entire protein, mechanism-agnostic resistance). Each step was driven by the prior generation's resistance mechanisms.

Why BeOne Medicines Dominates the MCL Trial Landscape

BeOne (formerly BeiGene) has two approved MCL drugs, zanubrutinib (Brukinsa, BTK inhibitor) and tislelizumab (PD-1 checkpoint inhibitor), and two investigational agents in MCL-relevant trials: sonrotoclax (BCL-2 inhibitor) and BGB-16673 (BTK degrader). The CELESTIAL-RRMCL Phase 3 trial is the direct test of BeOne's hypothesis that their proprietary BTKi + BCL-2i combination is superior to BTKi monotherapy, a strategy similar to the venetoclax + ibrutinib (VenEx) combinations studied in CLL, but using next-generation agents with potentially improved tolerability profiles.

The Post-CAR-T Problem in MCL

KTE-X19 (Tecartus) CAR-T produces high response rates in R/R MCL but durability is a challenge, approximately 50% of responders eventually relapse. The post-CAR-T setting is emerging as MCL's newest unmet need as more patients receive CAR-T in earlier lines. The NCI glofitamab trial (NCT07003295) directly addresses post-CAR-T MCL: rather than infusing CAR-T cells again (logistically challenging post-lymphodepletion), a bispecific T-cell engager redirects endogenous T cells to CD20+ tumor cells. This is particularly relevant because CD19-targeted approaches (like many CAR-T products) can select for CD19-negative escape, whereas glofitamab targets CD20, a distinct B-cell antigen.

FAQ

Frequently asked questions

What is sonrotoclax and what does the CELESTIAL-RRMCL Phase 3 trial test?
Sonrotoclax (BGB-11417) is BeOne Medicines's BCL-2 inhibitor, designed as a next-generation successor to venetoclax. BCL-2 (B-cell lymphoma 2) is an anti-apoptotic protein highly expressed in mantle cell lymphoma (MCL) that helps tumor cells evade programmed cell death. Venetoclax (Venclexta) is approved in CLL and AML and has shown activity in MCL off-label, but has no MCL-specific approval. The CELESTIAL-RRMCL Phase 3 trial (NCT06742996) tests sonrotoclax in combination with zanubrutinib (BeOne's BTK inhibitor, approved in MCL as Brukinsa) versus placebo plus zanubrutinib in adults with relapsed/refractory MCL. Early-phase data combining the two drugs reported response rates in the high 70s to low 80s percent. If positive, CELESTIAL-RRMCL would support a new combination standard of care in relapsed/refractory MCL.
What is pirtobrutinib (Jaypirca) and how does it work in BTK-inhibitor-resistant MCL?
Pirtobrutinib (Jaypirca, Eli Lilly) is a non-covalent BTK inhibitor: it binds BTK reversibly rather than forming the covalent bond at C481 that ibrutinib, acalabrutinib, and zanubrutinib require. This matters because the most common resistance mechanism to covalent BTK inhibitors is the C481S mutation in BTK, which prevents covalent bond formation and blocks drug binding. Pirtobrutinib binds BTK independently of C481S status, restoring kinase inhibition in cells that have evolved covalent-BTKi resistance. The FDA approved pirtobrutinib in January 2023 for relapsed/refractory MCL after at least two prior lines of therapy, including a covalent BTK inhibitor, based on the BRUIN trial (overall response rate 50%, complete response 13%, in patients previously treated with a covalent BTK inhibitor).
What is a BTK protein degrader, and how do investigational degraders differ from BTK inhibitors?
BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib) block BTK's kinase activity but leave the BTK protein intact, which allows resistance through protein overexpression, kinase-domain bypass mutations, or non-kinase BTK scaffolding functions. BTK degraders use a PROTAC (proteolysis-targeting chimera) or molecular-glue approach: they recruit a cell's own protein-disposal machinery to mark the BTK protein for degradation, eliminating the entire protein rather than just its activity. Several BTK degraders (from BeOne Medicines and Nurix Therapeutics, among others) are in early-phase trials in relapsed/refractory B-cell malignancies including MCL. The hypothesis is that degraders could overcome both C481S and non-C481S BTKi resistance by eliminating the protein entirely, regardless of mutation status.
What role does CAR-T cell therapy play in MCL?
Brexucabtagene autoleucel (Tecartus, KTE-X19) is an approved CAR-T therapy in MCL, initially approved in 2020 for relapsed/refractory MCL after two or more prior lines of therapy, later receiving full approval. In the pivotal ZUMA-2 trial cohort of BTK-inhibitor-exposed patients, it produced an overall response rate of 87% and a complete response rate of 62%. Roughly half of patients who respond will eventually relapse, and the post-CAR-T setting in MCL has no established standard of care; bispecific T-cell engagers and other novel agents are being investigated for patients who progress after CAR-T.
What is the current standard of care for mantle cell lymphoma?
MCL treatment is broadly stratified by patient fitness and line of therapy. For transplant-eligible patients in first-line treatment, intensive chemoimmunotherapy followed by autologous stem cell transplantation (ASCT) remains a standard for young, fit patients, though this is increasingly challenged by frontline BTK-inhibitor-containing regimens. Transplant-ineligible patients typically receive chemoimmunotherapy such as R-CHOP or bendamustine plus rituximab. In relapsed/refractory MCL, covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are generally used first; after progression on a covalent BTK inhibitor, options include pirtobrutinib or brexucabtagene autoleucel (CAR-T) if the patient has had two or more prior lines. After CAR-T failure, there is no established standard of care, and enrollment in a clinical trial is often recommended.

Track the CELESTIAL-RRMCL Phase 3 Trial

When BeOne posts enrollment updates or site openings for the sonrotoclax + zanubrutinib trial, see it in the next morning's digest.

Start Free: No Credit Card

Related Pages

Live trial data Data as of 2026-10-12, ClinicalTrials.gov

212 active trials, 107 recruiting.

Industry sponsors run 55 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 41.

Top industry sponsorActive trials
BeOne Medicines5
AstraZeneca4
Acerta Pharma BV3
Guangzhou Lupeng Pharmaceutical Company LTD.3
Beijing InnoCare Pharma Tech Co., Ltd.2

View the full Mantle Cell Lymphoma pipeline on the dashboard

Notable trials Ranked by recent tracked changes, ClinicalTrials.gov data as of 2026-10-12
TrialStatusLatest tracked changeSeen
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319RecruitingCompletion pushed from Jan 1, 2028 to Aug 1, 20282026-10-10
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously… NCT04783415Active, Not RecruitingCompletion pushed from Jul 21, 2026 to Jul 13, 20272026-10-07
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in… NCT05006716RecruitingCompletion pushed from Nov 2029 to Mar 20302026-10-06
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in… NCT07763210RecruitingInterventions modified2026-10-03
Cellular Immunotherapy Following Chemotherapy in Treating Patients With… NCT02153580Active, Not RecruitingCompletion pushed from Sep 2, 2026 to Aug 11, 20272026-10-03

Each trial page shows every change DataLookout has recorded for that trial.

Related reading

Spotting a trial in trouble before the status changes

Track these trials with DataLookout

DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.

Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.

Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.

Start free